查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1550381

动静脉瘻管设备市场 - 全球产业规模、份额、趋势、机会和预测，按类型、最终用途、地区和竞争细分，2019-2029F

Arteriovenous Fistula Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By End-use, By Region, and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 187 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2023 年全球动静脉瘻管器械市场(AVF) 估值为3.0012 亿美元，预计在预测期内将出现令人印象深刻的成长，到2029 年复合年增长率为7.25%。市场近年来经历了显着的增长和演变近年来，慢性肾臟病（CKD）患病率不断上升，以及对有效血液透析治疗的需求不断增加。动静脉内瘻管装置在确保血液透析的有效且安全的血管通路方面发挥关键作用，特别是对于末期肾病变（ESRD）患者。市场的成长受到几个关键因素的推动。首先，全球人口老化加剧导致 CKD 和 ESRD 发生率增加，增加了对血液透析程序的需求。动静脉瘻管（AV 瘻管）装置是一种医疗干预措施，用于在动脉和静脉（通常是手臂）之间建立直接连接，为血液透析治疗提供可靠的通路。血液透析是一种医疗程序，用于在人的肾臟不再正常运作时过滤血液中的废物和多余液体。 AV 瘻管装置通常用于需要定期进行血液透析治疗的末期肾臟病 (ESRD) 患者。动静脉瘻管是透过手术将动脉和静脉连接在一起形成的，通常位于前臂或上臂。这种连接会增加进入静脉的血流量，使其更大、更耐用，以便在血液透析过程中反覆插入针头。血流量的增加也有助于更有效地清除血液中的废物。动静脉内瘻管装置为长期血管通路提供了更好的选择，最大限度地降低了感染风险并优化了透析效率，这进一步推动了它们的采用。

市场概况
预测期 2025-2029
2023 年市场规模 30012万美元
2029 年市场规模 4.445亿美元
2024-2029 年复合年增长率 7.25%
成长最快的细分市场 AVF 创建设备
最大的市场 北美洲

医疗技术的进步也刺激了动静脉内瘻管设备的创新。製造商正在开发更俱生物相容性、耐用且不易出现併发症的设备。这些创新旨在提高患者的舒适度、减少干预频率并延长瘻管的寿命，从而改善患者的整体治疗效果。从地理上看，该市场表现出广泛的影响力，北美、欧洲、亚太地区和其他地区都为其成长做出了贡献。印度和中国等亚太地区发展中经济体的医疗基础设施和先进医疗手段显着增加，推动了对动静脉内瘻管设备的需求。然而，市场内部仍存在挑战。建立瘻管所需的复杂外科手术需要熟练的医疗保健专业人员，而瘻管的成熟期也增加了复杂性。替代血管通路方法，如动静脉移植物和中心静脉导管，继续使用，给动静脉瘻管装置市场带来竞争。由于 CKD 盛行率不断上升、医疗技术的进步以及医疗保健基础设施的扩大，全球动静脉内瘻管设备市场正在强劲成长。随着市场的不断发展，人们越来越重视研究和开发，旨在进一步提高这些设备的性能、耐用性和患者友善性。随着人们越来越关注改善血液透析患者的生活质量，动静脉瘻管设备市场可能仍然是现代肾臟病护理的重要组成部分。

主要市场驱动因素

慢性肾臟病 (CKD) 盛行率上升

血液透析治疗的需求不断增长

增加医疗支出

主要市场挑战

复杂的手术程序

瘻管成熟时间

主要市场趋势

远距医疗和远端监控

研究和临床试验

细分市场洞察

类型洞察

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球动静脉瘻管器械 (AVF) 市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依类型（AVF 建立设备、AVF 监控设备、AVF 维护设备）
    • 依最终用途（医院、心臟中心、其他）
    • 按地区
    • 按公司划分 (2023)
  • 市场地图

第 6 章：北美动静脉瘻管器械市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按最终用途
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 7 章：欧洲动静脉瘻管器械市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按最终用途
    • 按国家/地区
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第 8 章：亚太地区动静脉瘻管器械市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按最终用途
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲

第 9 章：南美洲动静脉瘻管器械市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按最终用途
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲动静脉瘻管设备市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按最终用途
    • 按国家/地区
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 併购
  • 产品开发
  • 最新动态

第13章：竞争格局

  • Medtronic plc
  • Becton, Dickinson and Company
  • Teleflex Incorporated
  • Fresenius Medical Care AG & Co. KGaA.
  • B. Braun SE
  • Poly Medicure Ltd.
  • NxStage Medical, Inc.
  • Laminate Medical Technologies Ltd.

第 14 章：策略建议

第 15 章：关于我们与免责声明

简介目录
Product Code: 23877

Global Arteriovenous Fistula Devices Market (AVF) was valued at USD 300.12 million in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.25% through 2029. The global arteriovenous fistula devices market has experienced significant growth and evolution in recent years, driven by the rising prevalence of chronic kidney diseases (CKD) and the increasing need for effective hemodialysis treatments. Arteriovenous fistula devices play a pivotal role in ensuring efficient and safe vascular access for hemodialysis, particularly in patients with end-stage renal disease (ESRD). The market's growth is propelled by several key factors. First, the growing aging population worldwide has contributed to an increased incidence of CKD and ESRD, thereby augmenting the demand for hemodialysis procedures. An arteriovenous fistula (AV fistula) device is a medical intervention used to create a direct connection between an artery and a vein, typically in the arm, to provide reliable access for hemodialysis treatment. Hemodialysis is a medical procedure used to filter waste and excess fluids from the blood when a person's kidneys are no longer functioning properly. The AV fistula device is commonly used in patients with end-stage renal disease (ESRD) who require regular hemodialysis treatments. The AV fistula is surgically created by connecting an artery and a vein together, usually in the forearm or upper arm. This connection causes increased blood flow into the vein, making it larger and more durable for repeated needle insertions during hemodialysis sessions. The increased blood flow also helps remove waste products from the blood more efficiently. Arteriovenous fistula devices offer a superior option for long-term vascular access, minimizing infection risks and optimizing dialysis efficiency, which has further fueled their adoption.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 300.12 Million
Market Size 2029USD 444.50 Million
CAGR 2024-20297.25%
Fastest Growing SegmentAVF Creation Devices
Largest MarketNorth America

The advancements in medical technology have also spurred innovation in arteriovenous fistula devices. Manufacturers are developing devices that are more biocompatible, durable, and less prone to complications. These innovations aim to enhance patient comfort, reduce intervention frequency, and prolong the lifespan of the fistula, thereby improving overall patient outcomes. Geographically, the market exhibits a widespread presence, with North America, Europe, Asia Pacific, and other regions all contributing to its growth. Developing economies in Asia Pacific, such as India and China, have seen a notable increase in healthcare infrastructure and access to advanced medical treatments, driving the demand for arteriovenous fistula devices. However, challenges remain within the market. The intricate surgical procedure required for fistula creation demands skilled healthcare professionals, and the maturation period of the fistula adds to the complexity. The alternative vascular access methods, such as arteriovenous grafts and central venous catheters, continue to be utilized, presenting competition to the arteriovenous fistula devices market. The global arteriovenous fistula devices market is witnessing robust growth due to the escalating prevalence of CKD, advancements in medical technology, and expanding healthcare infrastructures. As the market continues to evolve, there is a growing emphasis on research and development, aiming to further enhance the performance, durability, and patient-friendliness of these devices. With an ever-increasing focus on improving the quality of life for patients undergoing hemodialysis, the arteriovenous fistula devices market is likely to remain a crucial component of modern nephrology care.

Key Market Drivers

Rising Prevalence of Chronic Kidney Disease (CKD)

The rising prevalence of chronic kidney disease (CKD) has emerged as a significant driver shaping the global arteriovenous fistula devices market. CKD refers to the progressive and irreversible deterioration of kidney function over time, and it represents a growing public health concern worldwide. This escalating prevalence has profound implications for the demand and adoption of arteriovenous fistula devices. Several factors contribute to the increasing prevalence of CKD. Demographic shifts, including an aging global population, play a pivotal role. As individuals age, their kidneys naturally undergo changes, and older adults are more susceptible to kidney dysfunction. This demographic trend has led to a higher incidence of CKD cases, consequently driving the demand for renal replacement therapies such as hemodialysis. Secondly, the global surge in non-communicable diseases, particularly diabetes and hypertension, has amplified CKD rates. Both conditions are leading causes of kidney damage, with diabetes causing diabetic nephropathy and hypertension leading to hypertensive nephropathy. These comorbidities result in a higher likelihood of kidney function decline, necessitating renal replacement therapies like hemodialysis, which often requires arteriovenous fistula devices. The lifestyle factors, including unhealthy diets and sedentary behavior, contribute to the rise in CKD cases. Poor dietary choices and inadequate physical activity can contribute to obesity, diabetes, and hypertension, all of which increase the risk of kidney damage and CKD development. The increasing global awareness of CKD and its impact on public health has led to improved screening and early detection efforts. As more cases of CKD are identified in their early stages, the need for effective and reliable vascular access for hemodialysis, such as arteriovenous fistula devices, becomes even more pronounced.

Growing Need for Hemodialysis Treatment

The growing need for hemodialysis treatment has become a significant driving force in shaping the global arteriovenous fistula devices market. Hemodialysis is a life-sustaining medical procedure used to filter waste products and excess fluids from the blood when the kidneys fail to adequately perform these functions. This escalating demand for hemodialysis has direct implications for the adoption and utilization of arteriovenous fistula devices. One of the primary contributors to the increased need for hemodialysis is the rising prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD) on a global scale. As CKD progresses to its advanced stages, kidney function declines to the point where dialysis becomes essential for maintaining the body's internal balance. This has led to a growing population of patients who require regular hemodialysis sessions for survival. The changing disease patterns and lifestyle factors, such as the global surge in diabetes and hypertension, have contributed to the increase in ESRD cases. These conditions are known to accelerate kidney damage, leading to a higher likelihood of kidney function deterioration and the subsequent need for hemodialysis treatment. The availability of hemodialysis treatment has also expanded due to advances in medical infrastructure and technology. Healthcare systems in many countries have developed or improved their dialysis facilities, making this life-sustaining therapy more accessible to a larger number of patients. This, in turn, has bolstered the demand for arteriovenous fistula devices, which provide a durable and effective means of vascular access for hemodialysis. As the global population ages and the burden of chronic diseases continues to rise, the need for hemodialysis treatment is expected to further intensify. The arteriovenous fistula device market is poised to benefit from this trend as these devices offer a reliable and long-lasting solution for creating the necessary access points for hemodialysis procedures. Ensuring optimal vascular access becomes paramount to enhance patient outcomes and minimize complications, making arteriovenous fistula devices a critical component in meeting the growing need for hemodialysis treatment worldwide.

Increasing Healthcare Expenditure

The increasing healthcare expenditure across the globe has significant implications for the growth and development of the global arteriovenous fistula devices market. Healthcare expenditure encompasses the financial resources allocated to medical services, treatments, and technologies, and its upward trajectory has a direct impact on the demand for and utilization of arteriovenous fistula devices. As economies expand and healthcare systems evolve, there is a growing recognition of the importance of addressing chronic diseases and providing advanced medical interventions. Chronic kidney disease (CKD) and end-stage renal disease (ESRD) are among the conditions that require substantial healthcare resources, including renal replacement therapies like hemodialysis. Arteriovenous fistula devices play a pivotal role in hemodialysis, serving as a reliable and durable means of vascular access. The increasing healthcare expenditure enables healthcare systems to invest in the infrastructure, facilities, and medical devices necessary for delivering quality hemodialysis care, including the adoption of arteriovenous fistula devices. The availability of financial resources enables research and development initiatives aimed at advancing medical technologies, including arteriovenous fistula devices. Manufacturers can invest in designing and producing more innovative, patient-friendly, and efficient devices that align with evolving healthcare needs and quality standards. This continuous innovation not only enhances patient comfort and safety but also contributes to the growth of the arteriovenous fistula devices market.

Key Market Challenges

Complex Surgical Procedures

Complex surgical procedures in the context of the global arteriovenous fistula devices market refer to the intricate and skill-intensive techniques involved in creating and managing arteriovenous fistulas (AVFs) for hemodialysis access. AVFs are surgically constructed connections between an artery and a vein, usually in the arm, allowing for increased blood flow and a reliable access point for hemodialysis treatment. While AVFs offer numerous benefits, the complexity of the surgical procedures can present challenges and considerations within the market. The creation of an AVF involves delicate surgical techniques that demand a high level of expertise from medical professionals, typically vascular surgeons. The surgeon must identify suitable arteries and veins, make precise incisions, and skillfully connect them to establish a functional fistula. Proper placement, appropriate vessel size, and ensuring adequate blood flow are crucial aspects of the procedure. The surgery requires precision and a deep understanding of vascular anatomy to minimize complications and optimize the chances of successful maturation. The complexity of AVF procedures can impact the broader arteriovenous fistula devices market in several ways. Healthcare providers need to ensure that their medical staff is adequately trained and experienced in performing AVF surgeries. Manufacturers of AVF devices may focus on designing tools and technologies that simplify the surgical process, reduce complications, and improve patient outcomes. The patient education about the importance of optimal vascular access and the complexities involved can enhance patient cooperation and understanding.

Fistula Maturation Time

Fistula maturation time is a critical factor in the context of the global arteriovenous fistula devices market, referring to the period required for an arteriovenous fistula (AVF) to fully develop and become suitable for use in hemodialysis. Hemodialysis is a life-saving medical procedure that involves removing waste products and excess fluids from the blood when the kidneys are unable to perform this function adequately. AVFs are surgically created connections between an artery and a vein, enabling efficient blood flow and providing a reliable access point for hemodialysis. The maturation of an AVF is a complex physiological process. After the surgical creation of the AVF, the vein gradually enlarges and strengthens, adapting to the increased blood flow from the connected artery. This maturation process involves the remodeling of blood vessels, the growth of new vessels (angiogenesis), and changes in vessel wall characteristics. These changes are necessary to ensure the vein can withstand repeated needle insertions during hemodialysis and provide the necessary blood flow rates for effective treatment. The time required for an AVF to mature can vary widely among individuals. On average, it may take several weeks to a few months for an AVF to reach its optimal state. However, some AVFs may mature more quickly, while others might take longer due to factors such as the patient's overall health, vascular condition, and the specific anatomical characteristics of the AVF. For the global arteriovenous fistula devices market, understanding and addressing fistula maturation time are crucial. Healthcare providers, manufacturers, and policymakers must work together to develop strategies that expedite and optimize AVF maturation. This can involve advancements in surgical techniques, post-operative care protocols, and patient education to ensure that patients receive timely and effective hemodialysis through mature AVFs. By reducing maturation times and improving the success rate of AVFs, the market can contribute to enhancing patient outcomes, reducing healthcare costs, and improving the overall quality of care for individuals with kidney disease.

Key Market Trends

Telehealth and Remote Monitoring

Telehealth and remote monitoring are innovative approaches that have been increasingly integrated into the global arteriovenous fistula devices market, transforming the way healthcare providers manage and monitor patients with arteriovenous fistulas (AVFs) for hemodialysis access. These technologies leverage digital communication to facilitate medical consultations, follow-ups, and real-time monitoring without the need for in-person visits. Telehealth involves the use of telecommunications technology to provide healthcare services and consultations remotely. In the context of the arteriovenous fistula devices market, telehealth enables healthcare professionals to connect with patients virtually, discuss their AVF progress, address concerns, and provide guidance. This approach is particularly valuable during the critical phase of AVF maturation when patients may have questions or require support. Remote monitoring extends telehealth by enabling continuous or periodic tracking of AVF-related parameters. Specialized sensors or devices can be used to collect data on blood flow, pressure, and other relevant metrics. This data is transmitted to healthcare providers for analysis, allowing them to monitor the AVF's function and detect any abnormalities or complications in real time. Remote monitoring enhances patient safety and allows for timely intervention if issues arise. Patients can receive medical guidance and support from the comfort of their homes, reducing the need for frequent clinic visits and long travel times. This is especially advantageous for patients living in remote or underserved areas. Remote monitoring enables healthcare providers to detect early signs of AVF complications, such as stenosis or thrombosis, and intervene promptly. This can prevent serious issues and potentially reduce the need for hospitalizations. Telehealth and remote monitoring empower patients to actively participate in their AVF management. Patients can learn about AVF care, track their progress, and communicate with healthcare professionals, leading to better self-management and adherence. By minimizing unnecessary in-person visits and hospitalizations, telehealth and remote monitoring have the potential to reduce healthcare costs for both patients and providers. Remote monitoring generates valuable data that healthcare providers can analyze to make informed decisions about AVF management strategies. This data-driven approach enhances the quality of care. Early detection and intervention through remote monitoring can contribute to better AVF maturation rates, fewer complications, and improved patient outcomes.

Therefore, the telehealth and remote monitoring are transformative tools in the global arteriovenous fistula devices market. By enhancing patient engagement, enabling timely interventions, and providing efficient healthcare delivery, these technologies contribute to optimizing AVF management and improving the overall quality of care for individuals undergoing hemodialysis.

Research and Clinical Trials

Research and clinical trials play a vital role in advancing the global arteriovenous fistula devices market by fostering innovation, improving patient outcomes, and enhancing the understanding of arteriovenous fistula (AVF) creation, maturation, and management. These initiatives involve systematic investigations conducted by researchers and medical professionals to explore new techniques, technologies, and approaches to optimize AVF-related procedures. Research in the arteriovenous fistula devices market encompasses a wide range of studies, including basic laboratory research, translational studies, and clinical investigations. Researchers aim to deepen their understanding of vascular physiology, AVF maturation mechanisms, and factors that influence the success or complications of AVFs. By gaining insights into these aspects, researchers can develop strategies to expedite maturation, reduce complications, and improve overall AVF functionality. Clinical trials, a subset of research, involve human participants and are conducted to evaluate the safety, efficacy, and feasibility of new interventions or medical devices. In the context of the arteriovenous fistula devices market, clinical trials might focus on testing novel device designs, surgical techniques, or post-operative care protocols. These trials provide valuable evidence-based data that can guide healthcare practices and influence the adoption of new technologies.

Segmental Insights

Type Insights

In 2023, the Arteriovenous Fistula Devices Market was dominated by the AVF creation devices segment. This is attributed de to its critical role in hemodialysis access creation. AVF creation devices facilitate the surgical formation of arteriovenous fistulas, the preferred vascular access for hemodialysis patients due to superior long-term outcomes and lower complication rates. As hemodialysis prevalence rises globally, driven by increasing incidences of renal diseases, the demand for AVF creation devices surges accordingly. The advancements in AVF creation techniques and devices, coupled with healthcare initiatives promoting AVF as the preferred access type, further bolster the dominance of this segment in the market and is predicted to continue expanding over the coming years. This is due rising prevalence of End-stage renal disease (ESRD) and the growing number of individuals requiring dialysis treatment have created a higher demand for AVF procedures. The significance of AVF creation devices lies in their essential role in addressing the increasing need for dialysis treatment. These devices facilitate efficient vascular access, thereby enhancing patient care and elevating the overall quality of life for individuals undergoing dialysis.

Regional Insights

North America accounted for the largest revenue share in 2023. This is ascribed due to advancements in technology, low cost of services, and availability of skilled workforce at a lower cost than developed economies and are anticipated to propel regional market growth. Increasing regulatory focus on quality control for manufacturing is one of the key factors expected to drive the growth over the forecast period. North America has a significant burden of kidney disease, and AVF devices play a crucial role in providing vascular access for hemodialysis.

Key Market Players

Medtronic PLC

Becton, Dickinson and Company

Teleflex Incorporated

Fresenius Medical Care AG & Co. KGaA.

B. Braun SE

Poly Medicure Ltd.

NxStage Medical, Inc.

Laminate Medical Technologies Ltd.

Report Scope:

In this report, the Global Arteriovenous Fistula Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Arteriovenous Fistula Devices Market, By Type:

    AVF Creation Devices
    • Surgical Instruments
    • Vascular Grafts
    • Angioplasty Balloons
    • Others
    AVF Monitoring Devices
    • Doppler Ultrasound
    • Pressure Monitoring Systems
    • Others
    AVF Maintenance Devices
    • Central Venous Catheters
    • Stents
    • Others

Arteriovenous Fistula Devices Market, By End-Use:

    Hospitals Cardiac Centers Others

Arteriovenous Fistula Devices Market, By Region:

    North America
    • United States
    • Canada
    • Mexico
    Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    South America
    • Brazil
    • Argentina
    • Colombia
    Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Arteriovenous Fistula Devices Market.

Available Customizations:

Global Arteriovenous Fistula Devices Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Arteriovenous Fistula Devices (AVF) Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (AVF Creation Devices, AVF Monitoring Devices, AVF Maintenance Devices)
      • 5.2.1.1. By AVF Creation Devices (Surgical Instruments, Vascular Grafts, Angioplasty Balloons, Others)
      • 5.2.1.2. By AVF Monitoring Devices (Doppler Ultrasound, Pressure Monitoring Systems, Others)
      • 5.2.1.3. By AVF Maintenance Devices (Central Venous Catheters, Stents, Others)
    • 5.2.2. By End-use (Hospitals, Cardiac Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2023)
  • 5.3. Market Map

6. North America Arteriovenous Fistula Devices Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By End-use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Arteriovenous Fistula Devices Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By End-use
    • 6.3.2. Canada Arteriovenous Fistula Devices Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By End-use
    • 6.3.3. Mexico Arteriovenous Fistula Devices Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By End-use

7. Europe Arteriovenous Fistula Devices Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By End-use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Arteriovenous Fistula Devices Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By End-use
    • 7.3.2. France Arteriovenous Fistula Devices Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By End-use
    • 7.3.3. United Kingdom Arteriovenous Fistula Devices Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By End-use
    • 7.3.4. Italy Arteriovenous Fistula Devices Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By End-use
    • 7.3.5. Spain Arteriovenous Fistula Devices Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By End-use

8. Asia-Pacific Arteriovenous Fistula Devices Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By End-use
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Arteriovenous Fistula Devices Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By End-use
    • 8.3.2. Japan Arteriovenous Fistula Devices Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By End-use
    • 8.3.3. India Arteriovenous Fistula Devices Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By End-use
    • 8.3.4. South Korea Arteriovenous Fistula Devices Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By End-use
    • 8.3.5. Australia Arteriovenous Fistula Devices Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By End-use

9. South America Arteriovenous Fistula Devices Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By End-use
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Arteriovenous Fistula Devices Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By End-use
    • 9.3.2. Argentina Arteriovenous Fistula Devices Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By End-use
    • 9.3.3. Colombia Arteriovenous Fistula Devices Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By End-use

10. Middle East and Africa Arteriovenous Fistula Devices Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By End-use
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Arteriovenous Fistula Devices Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By End-use
    • 10.3.2. Saudi Arabia Arteriovenous Fistula Devices Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By End-use
    • 10.3.3. UAE Arteriovenous Fistula Devices Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By End-use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition
  • 12.2. Product Development
  • 12.3. Recent Developments

13. Competitive Landscape

  • 13.1. Medtronic plc
    • 13.1.1. Business Overview
    • 13.1.2. Company Snapshot
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As Reported)
    • 13.1.5. Recent Developments
    • 13.1.6. Key Personnel Details
    • 13.1.7. SWOT Analysis
  • 13.2. Becton, Dickinson and Company
  • 13.3. Teleflex Incorporated
  • 13.4. Fresenius Medical Care AG & Co. KGaA.
  • 13.5. B. Braun SE
  • 13.6. Poly Medicure Ltd.
  • 13.7. NxStage Medical, Inc.
  • 13.8. Laminate Medical Technologies Ltd.

14. Strategic Recommendations

15. About Us & Discalimer